444 related articles for article (PubMed ID: 36110399)
21. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
24. Immunotherapy in advanced gastric cancer, is it the future?
Coutzac C; Pernot S; Chaput N; Zaanan A
Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
28. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
29. The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors.
Nuvola G; Mollica V; Massari F; Suárez C
Immunotherapy; 2023 Dec; 15(17):1429-1433. PubMed ID: 37718694
[No Abstract] [Full Text] [Related]
30. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Gaynor N; Crown J; Collins DM
Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
[TBL] [Abstract][Full Text] [Related]
32. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
Ren Y; Song J; Li X; Luo N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
[TBL] [Abstract][Full Text] [Related]
33. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
Yu L; Sun M; Zhang Q; Zhou Q; Wang Y
Front Immunol; 2022; 13():982026. PubMed ID: 36159789
[TBL] [Abstract][Full Text] [Related]
34. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
Shan J; Han D; Shen C; Lei Q; Zhang Y
Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
[TBL] [Abstract][Full Text] [Related]
35. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
[TBL] [Abstract][Full Text] [Related]
36. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
39. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
